The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; PharmaMar; Roche Pharma AG
Consulting or Advisory Role - Amgen; PharmaMar; Roche Pharma AG
 
Travel, Accommodations, Expenses - PharmaMar
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): Results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial.
 
Gennaro Daniele
Honoraria - Bayer Schering Pharma
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Roche Pharma AG
Research Funding - PharmaMar; Roche Pharma AG
 
Giovanni Scambia
No Relationships to Disclose
 
Marilena Di Napoli
No Relationships to Disclose
 
Maria Ornella Nicoletto
No Relationships to Disclose
 
Enrico Breda
No Relationships to Disclose
 
Nicoletta Colombo
Honoraria - Amgen; Clovis Oncology; Merck Sharp & Dohme; PharmaMar; Roche Pharma AG
Consulting or Advisory Role - Amgen; Clovis Oncology; Merck Sharp & Dohme; PharmaMar; Roche Pharma AG
Research Funding - PharmaMar; Roche Pharma AG
 
Grazia Artioli
No Relationships to Disclose
 
Bruno Daniele
No Relationships to Disclose
 
Giovanni Lo Re
No Relationships to Disclose
 
Francesco Raspagliesi
No Relationships to Disclose
 
Valentina Chiappa
No Relationships to Disclose
 
Vanda Salutari
No Relationships to Disclose
 
Gabriella Ferrandina
No Relationships to Disclose
 
Stefano Greggi
No Relationships to Disclose
 
Alessandra Baldoni
No Relationships to Disclose
 
Maria Carmela Piccirillo
No Relationships to Disclose
 
Roldano Fossati
No Relationships to Disclose
 
Francesco Perrone
Honoraria - Amgen; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Roche; Roche
Patents, Royalties, Other Intellectual Property - THE MITO 16 programme partial funding; The MITO-11 trial funding from GSK; The STAD-1 partial funding from AMGEN
Travel, Accommodations, Expenses - Bayer Schering Pharma; Bayer Schering Pharma; Roche
 
Sandro Pignata
Honoraria - AstraZeneca; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Roche Pharma AG
Research Funding - AstraZeneca; Janssen; Roche Pharma AG